MAPK3 and breast carcinoma: Western blotting data (Figure 3) with Erk1/2 specific antibody indicate suppression of Erk1/2 phosphorylation with 50 μM (31.27 ± 16.71; P < .05) biochanin A treatment in SK-BR-3 breast cancer cells.